Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up

CONCLUSIONS: In conclusion, after severe COVID-19 pneumonia, persistent clinical symptoms and pulmonary parenchymal involvement would be inevitable in elder and smoker patients. Moreover, corticosteroid treatment in patients with severe parenchymal involvement was found to be effective in the improvement of radiological and functional parameters.PMID:37712369 | DOI:10.36141/svdld.v40i3.14418

Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - September 15, 2023 Category: Respiratory Medicine Authors: Sibel G ünay Izzet Selcuk Parlak Habibe Hezer Ebru Şengül Şeref Parlak Melike Sanem Umut Zeynep Hanc ıoğlu H ülya Çelenk Ergüden Yasin Kocaman Aynil Dalk ıran Ümran Sertçelik İrem Şerifoğlu Esmehan Akp ınar Muhammet Furkan G öktaş Meltem Source Type: research